|
clinical trials overview
Trans Molecular, Inc., has developed
an extensive ongoing clinical trial program for TM601, with a
focus is on evaluating labeled and unlabeled TM601 for treatment
of aggressive cancers with limited treatment options.
Transmolecular’s clinical trial program has
progressed significantly over the past few years.  I-TM601
was approved as an investigational drug in April, 2002, was granted
orphan status for patients with high-grade glioma, and has received
fast-track designation. A phase I/II trial evaluating I-TM601
in the treatment of high-grade glioma (glioblastoma multiforme,
anaplastic astrocytoma) has been completed; a phase II clinical
trial is currently ongoing. In addition, Transmolecular recently
gained FDA approval of an IND to investigate unlabeled TM601 based
on evidence that IV-administered, unlabeled TM601 has antitumor
effects of its own, potentially due to antiangiogenic activity.
TransMolecular is planning to conduct a clinical study to evaluate
the effects of unlabeled TM601 alone in the treatment of high-grade
glioma that is expected to begin enrolling patients in early 2008.
(click
for larger and printable version)
To learn more about our glioma and metastatic
tumor clinical study program
click
here.
For information about studies that are currently
recruiting patients, prospective patients or their physicians
should contact Amy Bock, TransMolecular's Senior
Director, Clinical Operations at 617-995-3050 x 316
or by email at bock@transmolecular.com
More information about Transmolecular clinical trials currently recruiting patients can also be found at the following websites:
|
